Detalhe da pesquisa
1.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Future Oncol
; 19(14): 961-973, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306090
2.
Molecular features and clinical outcome of lung malignancies in very young people.
Future Oncol
; 11(8): 1211-21, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25832878
3.
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Oncologist
; 19(4): 344-5, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24674875
4.
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
J Clin Oncol
; : JCO2400581, 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38819031
5.
Airway fistula closure after stem-cell infusion.
N Engl J Med
; 372(1): 96-7, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25551543
6.
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Lancet Respir Med
; 11(4): 354-366, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36535300
7.
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
J Thorac Oncol
; 18(11): 1568-1580, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37295609
8.
TRIM proteins in cancer.
Adv Exp Med Biol
; 770: 77-91, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23631001
9.
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
J Thorac Oncol
; 17(4): 568-577, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35026476
10.
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Lung Cancer
; 169: 67-76, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660971
11.
"Waiting and the waiting room: how do you experience them?" emotional implications and suggestions from patients with cancer.
J Cancer Educ
; 26(2): 388-94, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20204572
12.
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
J Immunother Cancer
; 7(1): 342, 2019 12 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31801624
13.
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.
Oncotarget
; 9(23): 16437-16450, 2018 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29662657
14.
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
J Clin Oncol
; 36(4): 342-349, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29240542
15.
Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors.
J Thorac Oncol
; 10(2): 392-6, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25611230
16.
Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K).
Onco Targets Ther
; 8: 1997-2003, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26316776
17.
Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?
Curr Pharm Des
; 20(24): 3863-74, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24138720
18.
Stem cell transplantation effectively occludes bronchopleural fistula in an animal model.
Ann Thorac Surg
; 97(2): 480-3, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24370201
19.
Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
Crit Rev Oncol Hematol
; 89(3): 358-65, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24156959
20.
Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E.
Onco Targets Ther
; 7: 697-702, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24855380